Drug Profile
Research programme: glutathione peroxidase mimetics - Synvista Therapeutics
Latest Information Update: 07 Apr 2009
Price :
$50
*
At a glance
- Originator Synvista Therapeutics
- Class
- Mechanism of Action Glutathione peroxidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Autoimmune disorders; Cardiovascular disorders; Liver disorders
Most Recent Events
- 17 Sep 2008 Preclinical trials in Atherosclerosis in USA (unspecified route)
- 24 Jul 2007 Alteon is now called Synvista Therapeutics
- 12 May 2006 Preclinical trials in Cardiovascular disorders in USA (unspecified route)